Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

NCT06764485 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT06764485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 13, 2025
Completion date
January 19, 2029
Enrollment
960 (estimated)
Sites
227

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer